LTC Intermediate Nursing Care

Intermediate nursing care is a level of care provided in long-term care (LTC) facilities for patients who require assistance with daily living activities, but not to the extent required by skilled nursing care. It is typically provided by licensed practical nurses (LPNs) or certified nursing assistants (CNAs).

Here are some key features of LTC intermediate nursing care:

• Definition: Intermediate nursing care is a level of care that falls between skilled nursing care and custodial care. It is designed for patients who require some assistance with daily living activities, but not to the extent required by skilled nursing care.

• Services: Intermediate nursing care services may include assistance with bathing, dressing, eating, and medication management, as well as physical therapy, occupational therapy, and speech therapy. The goal is to help patients maintain their independence and improve their quality of life.

• Setting: Intermediate nursing care is typically provided in LTC facilities, such as nursing homes or assisted living facilities.

• Payment: Payment for intermediate nursing care may come from a variety of sources, including private insurance, Medicaid, or out-of-pocket payments.

• Coverage: Coverage for intermediate nursing care varies depending on the insurance plan. Some plans may cover all or part of the costs, while others may have limitations or exclusions.

• Eligibility: Eligibility for intermediate nursing care may depend on the patient's medical condition and level of need. A physician or other healthcare professional may need to assess the patient's needs and determine the appropriate level of care.

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.